ethyl 2-butoxybenzoate | 289894-50-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-butoxybenzoate
• CAS: 289894-50-4
• 化学式: C₁₃H₁₈O₃
• mdl: MFCD20527425
• 分子量: 222.284
• InChiKey: LSCQUUWETLEULM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  水杨酸乙酯	2-hydroxy-benzoic acid ethyl ester	118-61-6	C9H10O3	166.177

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  2-丁氧基苯甲酸	2-butoxybenzoic acid	2200-81-9	C11H14O3	194.23

反应信息

• 作为反应物：
  描述：

  ethyl 2-butoxybenzoate 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 2-丁氧基苯甲酸
  参考文献：
  名称：

  WO2008/116141

  摘要：

  公开号：
• 作为产物：
  描述：

  正溴丁烷 、 水杨酸乙酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以77%的产率得到ethyl 2-butoxybenzoate
  参考文献：
  名称：

  Enantioselective Molecular Recognition between β-Sheets

  摘要：

  This communication asks whether homochiral or heterochiral interaction is preferred between enantiomeric beta-sheets and finds that homochiral pairing is strongly preferred. Interactions between beta-sheets occur widely among proteins through pairing of the hydrogen-bonding edges. Although the hydrogen-bonding edges of both l- and d-beta-sheets put forth the same pattern of hydrogen-bond donor and acceptor groups, the side chains point in opposite directions. Homochiral pairing of beta-sheets generates structures in which the pleats and side chains of adjacent beta-strands are parallel to each other, while heterochiral pairing of beta-sheets generates structures in which the pleats and side chains are antiparallel. To test which pairing is preferred, we have prepared and studied the interactions of beta-sheets 1a-d, which comprise all l-amino acids, and beta-sheets 2a-c, which comprise all d-amino acids. Previous studies in our laboratory have established that these compounds form well-defined dimers in organic solvents. In the current study, 1H NMR experiments establish that when the l-beta-sheets (1) are mixed with the enantiomeric d-beta-sheets (2), homochiral beta-sheet dimers predominate, and only small quantities of heterochiral beta-sheet dimers form. Ratios of homochiral and heterochiral dimers ranging from 95.8:4.2 to 98.5:1.5 are measured in CDCl3 at 253 K, which correspond to statistically corrected free-energy differences of 3.1-4.2 kcal/mol (0.6-0.8 kcal/mol per interacting residue). Possible explanations for the high enantioselectivity of molecular recognition between beta-sheets include favorable nonbonded contacts between the adjacent beta-strands of the homochiral beta-sheets and poor fit of the heterochiral beta-strands, which should twist in opposite directions.

  DOI：

  10.1021/ja031632z

文献信息

• Naproxen Derivatives by Enantioselective Decarboxylation
  作者：Henri Brunner、Peter Schmidt

  DOI：10.1002/1099-0690(200006)2000:11<2119::aid-ejoc2119>3.0.co;2-5

  日期：2000.6

  agent naproxen [(S)-1] which has to be used as the (S) enantiomer, involves the enantioselective decarboxylation of the 6-methoxynaphth-2-yl derivative 2 of 2-cyanopropionic acid. Compound 2 was stirred in THF at 15 °C with catalytic amounts of chiral bases, which abstracted the carboxyl proton. After decarboxylation, reprotonation of the anion of 6 afforded the enantiomerically enriched naproxen nitrile

  一种合成重要抗炎剂萘普生 [(S)-1] 的新催化方法，必须用作 (S) 对映异构体，涉及 2- 6-甲氧基萘-2-基衍生物 2 的对映选择性脱羧氰基丙酸。化合物 2 在 15 °C 的 THF 中与催化量的手性碱一起搅拌，提取羧基质子。脱羧后，6 的阴离子再质子化得到富含对映异构体的萘普生腈 6，其可水解为萘普生。筛选了多种碱基，发现金鸡纳生物碱具有最佳的对映选择性。因此，使用奎尼丁 10，(S)-6 获得高达 34% 的 ee。通过转变成 9-amino-9-deoxyepicinchona 生物碱的酰胺，可以增加对映体过量。最成功的 9-amino-9-deoxyepicinchonine 11 的 2-ethoxybenzamide 31a 产生高达 71.9% 的 ee (S)-6。环醚（如 THF）是合适的溶剂，在 15 °C 的温度下，大多数情况下 24 小时内转化是定量的。对于高对映选择性，5-10
• Macrocyclic Compounds And Methods Of Making And Using The Same
  申请人：Farmer J. Jay

  公开号：US20080045585A1

  公开（公告）日：2008-02-21

  The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

  本发明提供了一种用作治疗剂的大环化合物。更具体地说，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。
• MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：Farmer Jay J.

  公开号：US20120252747A1

  公开（公告）日：2012-10-04

  The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R 1 , R 2 , R 3 , D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.

  本发明提供了通式为的大环化合物，可用作治疗剂，或其药学上可接受的盐、酯、N-氧化物或前药，其中T、R1、R2、R3、D、E、F和G如本文所定义。更具体地，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。
• Triazole Compounds and Methods of Making and Using the Same
  申请人：Rib-X Pharmaceuticals, Inc.

  公开号：US20140094422A1

  公开（公告）日：2014-04-03

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I): wherein R 1 , R 2 , etc. are defined as in Claim 1.

  本发明提供了三唑大环化合物，可用作治疗剂。更具体地说，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。这些化合物由以下式（I）表示：其中，R1，R2等如权利要求书1中所定义。
• TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：Melinta Therapeutics, Inc.

  公开号：US20160152654A1

  公开（公告）日：2016-06-02

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I): wherein R 1 , R 2 , etc. are defined as in claim 1.

  本发明提供了三唑宏环化合物，其作为治疗剂具有用途。更具体地说，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。这些化合物由以下公式（I）表示：其中R1、R2等在权利要求书中定义。